Here are nine observations:
1. In 2017, the market is valued at $2 billion.
2. The market is expected to grow at a compound annual growth rate of 6.4 percent through 2027.
3. Rechargeable SCS are anticipated to continue dominating the market, with sales reaching $2.53 billion by 2027.
4. Non-rechargeable SCS will likely grow at a 4.6 percent CAGR.
5. The SCS application for failed back surgery syndrome will remain dominant throughout the forecast period. Sales will likely exceed $1 billion in 2017.
6. The complex regional pain syndrome comes in second for SCS application, with sales expected to grow at a 5.8 percent CAGR through 2027.
7. North America will lead the global market, with sales hitting $3 billion by 2027.
8. Western Europe comes in second, growing at a 6.1 percent CAGR through 2027. Eastern Europe and Japan will both grow at a 6 percent CAGR through 2027.
9. Boston Scientific, Medtronic, St Jude Medical, Nevro, Nuvectra, Stimwave and Saluda Medical lead the market.
More articles on devices:
Wright Medical enrolls 1st patient in U.S. Infinity Total Ankle System study: 5 points
InVivo cuts 39% of workforce, reports $9.4M net loss in Q3: 5 things to know
Global spine implants market to increase at 5.29% CAGR through 2020: 3 insights
